Science Spotlight | B Traxinger | Dec. 17, 2018
Hutch News | Sabin Russell | Nov. 30, 2018
A conversation in advance of World AIDS Day with pioneering HIV researcher Dr. Larry Corey
VIDD News | Aziel Gangerdine | June 26, 2018
An HIV vaccine regimen tested in an early-phase clinical trial elicited robust immune responses that appeared to be stronger than those observed in a landmark 2009 study showing that a vaccine can protect people from HIV infection.
Hutch News | Rachel Tompa | Feb. 16, 2018
Research studies are often built around an educated guess. What happens when those guesses are wrong?
Hutch News | Sabin Russell and Susan Keown | Dec. 28, 2017
A look back at notable discoveries in cancer immunotherapy, HIV prevention and more
Hutch News | Mary Engel | Dec. 1, 2017
As lights around the world glow red today, Fred Hutch-based researchers lead global effort to end the pandemic
Hutch News | Sabin Russell | June 29, 2017
An unexpected discovery in a herpes lab might bring relief to cancer patients
Science Spotlight | BL DeBuysscher | May 15, 2017
Human cytomegalovirus (CMV) is a common virus that infects almost half of people over 40, usually causing no symptoms.
Hutch News | Jan. 19, 2017
Dr. Larry Corey wins $2.6 million grant to explore using CAR T cells for HIV cure
Hutch News | Jan. 5, 2017
425 Magazine salutes Fred Hutch HIV researcher, community advocate
Hutch News | Mary Engel | Dec. 20, 2016
Pritelivir reduces viral shedding and lesions better than valacyclovir, study shows
Hutch News | Nov. 4, 2016
Seattle magazine tabs Dr. Larry Corey for Seattle ‘Hall of Fame’
Hutch News | Mary Engel | Aug. 8, 2016
A revolution in cancer care may offer clues to a cure or remission for HIV/AIDS
Hutch News | Mary Engel | July 25, 2016
Beyond HIV treatment to vaccines and a cure, calls to finish the job — and leave no one behind
Hutch News | Mary Engel | July 20, 2016
'The HIV vaccine field is open for business,' said Fred Hutch's Dr. Larry Corey at International AIDS Society's biennial meeting in Durban, South Africa
Hutch News | Mary Engel | July 19, 2016
At International AIDS Conference, researchers are optimistic as two new HIV vaccine trials are set to explore different approaches for protection
Hutch News | July 18, 2016
The last time the International AIDS Conference was in Africa, AIDS denialism was at its height; two Fred Hutch leaders in the fight to end HIV talk about where we’ve been – and what’s next
Hutch News | Mary Engel | July 13, 2016
DefeatHIV receives second five-year grant from NIH to research gene and cell therapies
Hutch News | June 17, 2016
Dr. Larry Corey receives commissioned portrait
Hutch News | Mary Engel | June 13, 2016
After helping pave the way to HIV treatment, Dr. Larry Corey wants a vaccine — and a cure
Hutch News | Rachel Tompa | June 7, 2016
25 years after his death, infectious disease expert Dr. Joel Meyers honored at inaugural symposium in his name
Hutch News | Mary Engel | May 18, 2016
Scientists give go-ahead for what could become the first licensed vaccine against the AIDS virus
Hutch News | Mary Engel | Apr. 7, 2016
A ‘landmark’ clinical trial called the AMP study launches on three continents to test HIV-blocking super antibodies
VIDD News | Mindy Miner | Dec. 7, 2015
One hurdle in HIV vaccine development is because genetically distinguishable strains (clades) of HIV circulate in different areas of the globe.
Hutch News | Mary Engel | Dec. 2, 2015
HBO’s ‘Countdown to Zero,’ featuring Fred Hutch researchers, shows the pandemic remains, but fresh hope abounds
Hutch News | Mary Engel | Dec. 1, 2015
A World AIDS Day Q&A with Fred Hutch’s Dr. Larry Corey, featured in HBO special report
Hutch News | Oct. 21, 2015
Study determines types of immune responses that an HIV vaccine may need to achieve protection against infection
Hutch News | Linda Dahlstrom | May 8, 2014
Building on career of life-saving research, Corey shifts full-time focus to the lab in quest for HIV and herpes vaccines, better cancer treatments
Hutch News | Dr. Sabrina Richards and Andrea Detter | Apr. 24, 2014
Xconomy Forum at Fred Hutch highlights excitement of recent progress, future promise
VIDD News | Mindy Miner | Mar. 18, 2014
Thirty years ago, Seattle scientists were instrumental in demonstrating that the drug acyclovir was efficacious for curbing HSV-2 symptoms and promoting genital ulcer healing.
VIDD News | Mindy Miner | Jan. 24, 2014
The research community has developed several biomedical and behavioral interventions for the prevention of HIV in the last six years.
Hutch News | Dec. 17, 2013
NIH funding will propel large-scale HIV vaccine clinical trials in South Africa and beyond
Hutch News | Dec. 4, 2013
Fred Hutch and Memorial Sloan-Kettering Cancer Center, along with pediatric partner Seattle Children’s Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer.
VIDD News | Mindy Miner | Nov. 4, 2013
For unknown reasons, the pandemic A/H1N1 influenza virus (pH1N1) is more deadly in indigenous populations around the world than those of European/Caucasian descent.
Hutch News | Deborah Bach | Oct. 25, 2013
Week-long meeting, lab opening mark start of journey toward successful HIV vaccine, said Dr. Larry Corey
Hutch News | May 15, 2013
Fred Hutch today called on Congress to support restoring full funding to the National Institutes of Health (NIH), which supports pioneering research that saves lives.
Hutch News | Dean Forbes | May 9, 2013
Discovery by Dr. Larry Corey and colleagues has implications for development of vaccine to prevent and treat HSV-2, similar infections
VIDD News | Mindy Miner | Mar. 3, 2012
Approximately 1 million people in the United States are currently living with or in remission from hematologic malignancies, including leukemia, lymphoma and myeloma.
VIDD News | Mindy Miner | Jan. 5, 2012
Despite the efficacy of acyclovir and valacyclovir in reducing herpes genital lesions, antiviral therapy decreases the risk of transmission by only 48%.
VIDD News | Mindy Miner | Dec. 1, 2011
Adeno-associated virus (AAV) is a paravirus that has been considered an attractive candidate vaccine vector (or “delivery system”) due to its presumed nonpathogenicity and specific integration into the host’s DNA.
VIDD News | Mindy Miner | Nov. 7, 2011
Herpes simplex virus 2 (HSV-2) is a sexually transmitted disease that can cause genital ulcers as a result of viral reactivation from a latent state.
VIDD News | Stephen Voght | Oct. 3, 2011
Human herpesvirus-8 (HHV-8) is a human oncovirus and the key pathogenic agent in certain cancers: Kaposi sarcoma, primary effusion lymphoma and certain types of multicentric Castleman disease.
VIDD News | Mindy Miner | Oct. 3, 2011
In the last 12 years, approximately 15 million new HIV infections occurred.
VIDD News | Mindy Miner | Sept. 16, 2011
Herpesviruses are known for causing recurrent clinical episodes, usually in the form of a sore on the skin or genital surfaces.
VIDD News | Sept. 5, 2011
A VIDD study has found that patients co-infected with HIV and genital herpes are not always aware of herpes-induced ulcers, suggesting that new methods to prevent herpes and HIV transmission in this population are needed.
VIDD News | Rachel Tompa | July 11, 2011
The HVTN’s Step study, a large phase IIb trial to test the efficacy of a Merck adenovirus 5 (Ad5)-based HIV vaccine, was halted in 2007 when mid-trial analyses showed that the vaccine had no effect in preventing HIV infection.
VIDD News | Stephen Voght | June 10, 2011
An effective HIV vaccine designed to elicit T-cell responses must either induce broad responses to a wide variety of epitopes, or protein pieces, in order to cover the extensive sequence variability in circulating HIV-1 strains, or it must be focused on a few highly conserved epitopes expected to be present in the majority of circulating strains likely to be encountered by a vaccinated individual.
VIDD News | Stephen Voght | June 6, 2011
A major obstacle to the development of an effective HIV vaccine is the high genetic diversity among global HIV-1 isolates, most notably in the envelope protein (Env) that makes up the virus’ outer shell.
Hutch News | July 30, 2010
The Fred Hutch board of trustees today announced the selection of Lawrence Corey, M.D., an internationally renowned expert in virology, immunology and vaccine development, as its new president and director.
Hutch News | July 6, 2010
The three-year-old Vaccine and Infectious Disease Institute at Fred Hutchinson Cancer Research Center has become the Hutchinson Center's fifth scientific research division and has been renamed the Vaccine and Infectious Disease Division (VIDD).
Hutch News | Oct. 13, 2008
Larry Corey, M.D., senior vice president and co-director of the Vaccine and Infectious Disease Institute at Fred Hutchinson Cancer Research Center, today was named as one of 65 new members of the prestigious Institute of Medicine (IOM).
Hutch News | May 1, 2007
Fred Hutch has established a new Vaccine and Infectious Disease Institute to develop and implement prevention strategies for globally important infectious diseases, including HIV, malaria and cancer.
Hutch News | Feb. 21, 2007
The association between genital herpes and higher viral loads of HIV-1 in HIV-infected persons is strong enough to warrant more routine testing for the herpes virus in HIV-positive patients, as well as additional clinical studies of the co-infections, according to an editorial to be published in the Feb. 22 New England Journal of Medicine.
Hutch News | Dec. 31, 2003
An international team of researchers finds that taking a single daily dose of an approved antiviral drug known as valacyclovir can reduce the transmission of genital herpes to uninfected partners by 50 percent.
Hutch News | May 25, 2000
The National Institute of Allergy and Infectious Diseases announced today the formal establishment of a worldwide HIV Vaccine Trials Network (HVTN).
Hutch News | May 25, 2000
The worldwide search for an HIV vaccine received a boost today as the National Institute of Allergy and Infectious Diseases (NIAID) announced funding of nine U.S. clinical units of the new HIV Vaccine Trials Network (HVTN).